BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy · 05 Oct 2026
After the PCAC Vote: What the Six-Peptide 503A Recommendation Means in Practice — and How Long the Road to Legal Compounding Remains
The FDA's Pharmacy Compounding Advisory Committee backed BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the 503A Bulks List in July 2026 — overriding its own staff. Three months on, legal compounding status has not changed, and formal rulemaking is expected to run at minimum eight to 24 months. This briefing maps the procedural steps still ahead and what they mean for UK research procurement.
Read briefing →
Industry & Community
Samsung Biologics / PolyPeptide: What the Tender Close on 12 October Means for Peptide API Supply Chains
The main acceptance window for Samsung Biologics' CHF 1.46 billion all-cash offer for Swiss peptide CDMO PolyPeptide Group closes at 4 p.m. Swiss time on 12 October 2026. With a 40% premium, unanimous board support, and the majority shareholder committed to tender, the transaction is broadly expected to clear — reshaping the ownership of one of Europe's largest peptide API manufacturing networks at a moment of acute GLP-1 supply-chain pressure.
04 Oct 2026
Research Pipeline
GHK-Cu: What a Fresh Diabetic Wound Study and a Recruiting Phase 2 Trial Mean for the Copper Peptide's Research Standing
A new Carbohydrate Polymers study and a Phase 2 wound-healing trial currently recruiting signal renewed preclinical and early clinical momentum for GHK-Cu. Here is what laboratory procurement teams need to know about the peptide's mechanism, evidence base, and regulatory position in the UK and US.
03 Oct 2026
Research Pipeline
EASD Milan 2026: Three Datasets That Reframe the Next Wave of Peptide-Based Obesity Treatments
The 62nd Annual Meeting of the European Association for the Study of Diabetes closed in Milan on 2 October 2026 with three datasets of direct relevance to peptide researchers and procurement professionals: Phase 3 efficacy data for olatorepatide, real-world switching evidence for oral semaglutide, and Phase 2 muscle-preservation results for trevogrumab combined with semaglutide.
02 Oct 2026
Pharma & GLP-1
Lilly at EASD 2026: Retatrutide's TRIUMPH-2 Phase 3 Readout, Foundayo's Lancet Cardiovascular Data, and What eloraTZP Signals for the Next Generation of Incretin Combinations
Eli Lilly presented three significant cardiometabolic datasets at the 62nd EASD Annual Meeting in Milan this week. Retatrutide's TRIUMPH-2 Phase 3 trial reported up to 20.8% body-weight reduction in adults with obesity and type 2 diabetes; ACHIEVE-4 Foundayo data, simultaneously published in The Lancet, met cardiovascular non-inferiority versus insulin glargine; and Phase 2 eloraTZP results offered the first clinical look at a tirzepatide-amylin combination. The readouts reinforce Lilly's…
01 Oct 2026
Pharma & GLP-1
Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in a Deal Worth Up to $2.6 Billion
Novo Nordisk announced on 29 September 2026 that it has licensed HRS-1596, a phase 1-ready oral GLP-1/GIP dual receptor agonist from China's Hengrui Pharma in a deal valued at up to $2.6 billion. The compound carries the potential for once-weekly oral dosing — a frequency not yet achieved by any approved GLP-1 agent — though no human clinical data has been disclosed.
30 Sep 2026
Research Pipeline
Kailera Therapeutics and the Ribupatide Franchise: Inside the GLP-1 Challenger That Went Public With $719 Million and a Four-Asset Obesity Pipeline
Kailera Therapeutics, the Waltham-based clinical-stage company that raised $719 million in its April 2026 IPO, is running four simultaneous GLP-1 programmes — injectable and oral ribupatide, a small-molecule oral agonist, and a tri-agonist — to challenge Novo Nordisk and Eli Lilly. This briefing examines the ribupatide evidence base, the Hengrui partnership underpinning global access, upcoming data milestones, and what the strategy means for the research-procurement community.
29 Sep 2026
Research Pipeline
Epitalon: What the Pineal Tetrapeptide's 40-Year Research Record Actually Shows — And Where Its Regulatory Status Stands After the July 2026 PCAC Vote
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology with over four decades of preclinical research in ageing biology, telomere biology, and melatonin regulation. On 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7–4 to recommend it for the 503A Bulks List — overriding the FDA's own staff recommendation against inclusion — though formal rulemaking has not yet begun and it remains unlicensed in…
28 Sep 2026
Pharma & GLP-1
CagriSema's FDA Decision Window: What Novo Nordisk's Dual-Peptide Obesity Combination Means for Researchers and UK Access
Novo Nordisk's CagriSema — a fixed-dose combination of semaglutide and cagrilintide — is approaching an FDA decision expected in Q4 2026. As the first injectable amylin–GLP-1 combination to reach the regulatory finish line, its approval or rejection will determine whether dual-peptide combinations become the next standard of care. No MHRA submission has been publicly confirmed, leaving UK availability some way off.
27 Sep 2026
Industry & Community
Same Day, Different Strategies: How Lilly's $6.5 Billion Houston Groundbreaking and Novo's Capital Markets Day Reveal Diverging Paths in the Oral GLP-1 Manufacturing Race
On 21 September 2026, Eli Lilly broke ground on a $6.5 billion API facility in Houston and Novo Nordisk hosted its Capital Markets Day in London, where it pledged to scale oral GLP-1 manufacturing tenfold by 2030. The two announcements — made on the same day — illuminate fundamentally different production strategies and have direct implications for the peptide supply chain.
26 Sep 2026
Research Pipeline
Beyond Semaglutide and Tirzepatide: What a September 2026 Systematic Review Reveals About the Next Wave of GLP-1 Peptide Candidates
A systematic review published in the Annals of Internal Medicine on 18 September 2026 consolidates placebo-subtracted weight-loss data across 38 randomised controlled trials and 25,816 participants, offering the clearest cross-compound comparison to date. The findings contextualise where approved agents stand and how emerging multi-agonist peptides — retatrutide, amycretin, and a crop of oral candidates — are reshaping the development landscape.
25 Sep 2026
Regulatory & Policy
Two Months After the PCAC Vote: Where BPC-157, TB-500, Semax and Three Other Peptides Stand on the Road to the 503A Bulks List
The FDA's Pharmacy Compounding Advisory Committee recommended six peptides for 503A inclusion in July 2026 — but the votes were non-binding, FDA staff opposed all seven, and formal rulemaking has not yet begun. This briefing maps the full regulatory journey still ahead and what it means for procurement professionals today.
24 Sep 2026